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Abstract
Background: Atypical uterine leiomyomas show benign behavior. However, the distinction between leiomyomas
and leiomyosarcomas may at times be problematic. We report a rare case of atypical uterine leiomyoma. We try to
investigate potential immunohistochemical parameters that could be essential to distinguish cases of malignant
smooth muscle tumors and those of uncertain or borderline histology.
Case presentation: A 56-year-old white ethnic Albanian woman from Kosovo presented with uterine bleeding
because of uterine multiple leiomyomas. A hysterectomy with unilateral adnexectomy was performed. Her
hysterectomy specimen contained multiple leiomyomas in submucosal, intramural and subserosal locations.
The leiomyomas were well demarcated, firm and white with a whorled cut surface and one had foci of hemorrhage.
Histology of most of the leiomyomas showed a whorled (fascicular) pattern of smooth muscle bundles separated by
well-vascularized connective tissue. Smooth muscle cells were elongated with eosinophilic or occasional fibrillar
cytoplasm and distinct cell membranes. Some of them developed areas of degeneration including hyaline change,
with less than five mitotic figures per ten high power fields in most mitotically active areas, and no significant atypia.
One leiomyoma was characterized by moderately to severely pleomorphic atypical tumor cells with low mitotic
counts and no coagulative tumor cell necrosis. Immunohistochemistry showed strong immunoreactivity for vimentin,
smooth muscle actin and desmin, while cyclin-dependent kinase inhibitor 2A (p16), and B-cell lymphoma 2 (bcl-2)
showed focal immunoreactivity, estrogen and progesterone were positive, Ki-67 expressed a low proliferation index,
whereas p21 and tumor suppressor gene p53 were negative.
Conclusions: The combination of evaluation of conventional morphologic criteria with cyclin-dependent kinase
inhibitor 2A (p16), p21, progesterone, B-cell lymphoma 2, tumor suppressor gene p53 and Ki-67 expression may be of
great value in the assessment of uterine smooth muscle tumors of uncertain or borderline histology.
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Background
Atypical leiomyomas (ALMs) are characterized by mod-
erately to severely pleomorphic atypical tumor cells with
low mitotic counts and no coagulative tumor cell necro-
sis. Despite the worrisome histologic features, most tu-
mors have shown benign behavior. However, most
studied patients had total hysterectomies, and very few
patients who had myomectomy alone have had long-
term follow-up [1].
Individual features, such as hypercellularity, necrosis,
nuclear atypia, mitotic figures, and intravascular growth,
are ominous but must be interpreted with caution be-
cause variants of benign leiomyomas (LMs) may contain
such changes [2].
ALM when unassociated with either coagulative tumor
cell necrosis or a mitotic index in excess of 10 mitotic
figures per 10 high power fields (HPFs) and cytological
atypia, even when severe, is an unreliable criterion for
identifying clinically malignant uterine smooth muscle
tumors. These atypical cells have enlarged hyperchro-
matic nuclei with prominent chromatin clumping (often
smudged). Large cytoplasmic pseudonuclear inclusions
often are present. The atypical cells may be distributed
throughout the LM (diffuse) or they may be present fo-
cally (possibly, multifocally). When the atypia is at most
multifocal and the neoplasm has been completely
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sampled, such tumors are designated “ALM with min-
imal, if any, recurrence potential.” Such lesions have be-
haved benignly except for a single reported case [3].
There are studies suggesting that uterine tumors clas-
sified as smooth muscle tumors of uncertain malignant
potential (STUMPs) using criteria proposed by Stanford
investigators are usually clinically benign but should be
considered tumors of low malignant potential because
they can occasionally recur, in some cases, years after
hysterectomy. Of note, the two recurrent tumors were
the only ones that were strongly immunoreactive for
cyclin-dependent kinase inhibitor 2A, multiple tumor
suppressor 1 (p16) and p53, supporting earlier observa-
tions that these markers may be helpful in the prediction
of the behavior of STUMPs. Patients diagnosed with
STUMPs should receive long-term surveillance [4].
The p16 protein has been identified as a tumor sup-
pressor protein, which binds specifically to the cyclin-
dependent kinase 4 (CDK4), inhibiting the catalytic ac-
tivity of the CDK4-cyclin D complex, and thereby acts
as a negative cell cycle regulator.
It has been shown that p16 might play an important
role in sarcomagenesis. Furthermore, p16 might be a
useful immunohistochemical marker, which could help
to distinguish cases of smooth muscle tumors in which
histologic features are ambiguous or borderline, but the
use of p16 in a diagnostic setting should await further
clinical studies and clarification of the mechanisms [5].
In uterine leiomyosarcomas (LMSs) p16 is overex-
pressed compared with LMs, benign LM variants and
STUMPs. In combination with p53 and Mib1 (a mono-
clonal antibody), p16 may be of value as an adjunct to
morphological examination in the assessment of prob-
lematic uterine smooth muscle tumors, although further
large-scale studies with follow-up are necessary to con-
firm this [6].
In cases in which the type of necrosis is uncertain (co-
agulative tumor cell versus hyalinized), the addition of
p16 may aid in discerning a subset of STUMP that
should be classified as LMS [7].
Case presentation
A 56-year-old white ethnic Albanian woman from
Kosovo presented with uterine bleeding because of uterine
multiple LMs. A hysterectomy with unilateral adnexect-
omy was performed. Histological diagnosis was multiple
uterine LMs and an atypical uterine LM.
Macroscopy
Her hysterectomy specimen contained multiple LMs in
submucosal, intramural and subserosal locations. The
LMs were well demarcated, firm and white with a
whorled cut surface and one had foci of hemorrhage.
Histology and immunohistochemistry
Histology of most of the LMs showed a whorled (fasci-
cular) pattern of smooth muscle bundles separated by
well-vascularized connective tissue. Smooth muscle cells
were elongated with eosinophilic or occasional fibrillar
cytoplasm and distinct cell membranes. Some of them
developed areas of degeneration including hyaline
change, with less than five mitotic figures per ten HPFs
in most mitotically active areas, and no significant atypia
(Figs. 1, 2 and 3). One leiomyoma was characterized by
moderately to severely pleomorphic atypical tumor cells
with low mitotic counts and no coagulative tumor cell
necrosis. Immunohistochemistry showed strong immuno-
reactivity for vimentin (Fig. 4), smooth muscle actin (SMA)
(Fig. 5) and desmin (Fig. 6), while p16 (Cyclin-dependent
kinase inhibitor 2A) showed focal immunoreactivity
(Fig. 7), estrogen (ER) and progesterone (PR) were posi-
tive (Figs. 8 and 9), Ki-67 (a monoclonal antibody)
Fig. 1 Atypical cells, hematoxylin and eosin stain 10×
Fig. 2 Atypical cells between fascicles of smooth muscle cells,
hematoxylin and eosin stain 20×
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expressed a low proliferation index (Fig. 10), whereas
p21 and p53 were negative.
The final diagnosis of our case was ALM.
Discussion
Among cases in which adjacent non-neoplastic tissue
was well visualized, all were found to have pushing mar-
gins. The average tumor size was 6.8 cm. The patients’
average age was 42.5 years. In all cases, the initial diag-
nostic procedure was hysterectomy or myomectomy.
ALM has a low rate of extrauterine intra-abdominal
recurrence (<2 %) with a negligible risk for distant me-
tastasis. Patients may be treated by myomectomy alone
with successful pregnancy, but should be monitored for
local intrauterine residual/recurrent disease [8].
In our case report, the tumor size was 5 cm, the pa-
tient’s age was 56 years and the diagnostic procedure
was hysterectomy. We suggested follow-up of the patient
in order to detect eventual recurrent tumor.
Cell cycle regulatory protein expression by immuno-
histochemical assay may have diagnostic utility in the
distinction of uterine LMS from LM variants. Protein
expression of p16, p21, p27 and p53 was evaluated by
immunohistochemistry on 44 ALMs, 16 LMSs and
eight cellular LMs. The ALM with extrauterine recur-
rence was diffusely positive for p21, but showed only
weak focal (<33 %) staining for all other cell cycle
markers [9].
We have evaluated p16 and p21 expressions in uterine
smooth muscle tumors in order to determine whether
p16 and p21 have a potential value in the differential
diagnosis of problematic cases [10].
Likewise, our case showed focal staining for p16 and
no staining for p21. In this way, these two cell cycle
regulatory protein expression antibodies represented
again their potential value in the distinction of ALM
from LMS.
Bcl-2 protein is an apoptosis-inhibiting gene product
that prevents the normal course of apoptotic cell death in
Fig. 3 Atypical cells, hematoxylin and eosin stain 20×
Fig. 4 Vimentin+, 20×
Fig. 5 Smooth muscle actin+, 20×
Fig. 6 Desmin+, 20×
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a variety of cells. In addition, bcl-2 can promote cell repli-
cation by reducing the requirement for growth factors.
This protein seems, therefore, to play an important role in
the growth of tumors. The different expression of bcl-2 in
uterine LMs, STUMPs and LMSs has been investigated.
Bcl-2 was expressed more frequently and more strongly
in LMs compared with LMSs and STUMPs. The stronger
bcl-2 expression in benign LMs and the better clinical
outcome of bcl-2-positive LMS indicate that this protein
seems to act as a good prognostic factor [11].
Similarly, bcl-2 in our case showed positive staining of
atypical cells, supporting the diagnosis of ALM.
There are studies that have observed significant differ-
ences of steroid receptor expression between uterine
LM, STUMP and LMS. The PR receptor may be an es-
pecially useful marker to distinguish cases of malignant
smooth muscle tumors in which histological features are
ambiguous or borderline [12].
Correspondingly, the results of our case report showed
intense staining for PR and ER receptors that
represented another proof of the benign nature of the le-
sion, contrary to LMS that has been shown to have weak
or no expression of steroid receptors.
Ki-67 antigen expression may be a useful immunohis-
tochemical parameter to distinguish between cases of
malignant smooth muscle tumors and those of uncertain
or borderline histology [13].
The Ki-67 proliferation index was very low (<10 %) in
our case, which represented a reliable standard to differ-
entiate the uncertain or borderline nature of the lesion
from the LMS.
Significant differences were observed between LM and
STUMP expression for Ki-67. We considered that more
diagnostic criteria and parameters for diagnosis in doubt-
ful cases among the three entities should be established.
Immunoassaying for Ki-67, p53 and PR are such parame-
ters. The panel of their expression in specific case eases
diagnosis [14].
All LMs as well as ALMs and STUMPs were stained
intensely for PR. Conversely, LMS was strongly stained
Fig. 7 Cyclin-dependent kinase inhibitor 2A, focally positive, 20×
Fig. 8 Estrogen+, 40×
Fig. 9 Progesterone+, 40×
Fig. 10 Ki-67 low proliferation index (10 %), 20×
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with p53, while the three non-sarcomatous groups
(STUMP, ALM and LM) were either entirely negative or
weakly stained for p53. Combined high PR and low p53
expression was seen in all examined cases of the non-
sarcomatous group including the STUMP cases and
none of the LMS cases. Therefore, it represents a “be-
nign” profile with 100 % specificity in diagnosis of a
non-sarcomatous tumor [15].
Combined high PR and negative p53 expression has
been shown in our case as well, helping us to exclude
the sarcomatous nature of the lesion.
We did not observe p53 immunoreactivity in any of 18
(0 %) LMs, but we did observe it in one of six (17 %)
STUMPs, and 16 of 34 (47 %) LMSs. Reactivity was not
observed in the surrounding non-neoplastic uterine
smooth muscle. Strong p53 overexpression in the LMSs
was significantly associated with high-grade morphology
(P=.013) and a high stage at the time of presentation
(P=.021) [16].
The absence of p53 immunoreactivity in our case
defined the benign profile of the tumor with high
specificity.
Conclusions
The distinction between ALMs, STUMPs and LMSs
may at times be problematic. Therefore, the combination
of evaluation of conventional morphologic criteria with
p16, p21, PR, bcl-2, p53 and Ki-67 expression may be of
great value in the assessment of uterine smooth muscle
tumors of uncertain or borderline histology.
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